HAMILTON, Bermuda, Oct. 19, 2016 /PRNewswire/ -- Roivant
Sciences Ltd., an innovative biopharmaceutical company focused on
developing promising drug candidates to improve the lives of
patients and their families, has expanded its Board of Directors
through the appointment of Patrick
Machado as its second independent director. Prior to joining
the board of Roivant Sciences, Mr. Machado was a co-founder of
Medivation and served as its Chief Financial Officer from 2004 to
2014. He also served as a director of Medivation through
September 2016.
"We are delighted to welcome Patrick
Machado to our board," said Vivek
Ramaswamy, Founder and Director of Roivant Sciences.
"Roivant will benefit greatly from Pat's judgment and experience,
including helping to build one of the most admired biotech
companies of the past decade. I look forward to working with Pat
and the rest of our team to build Roivant as a biopharmaceutical
company of the future."
"I am impressed with the diverse drug pipeline that Roivant has
built in a short period of time, and I admire the company's
relentless focus on improving the lives of patients by creating a
more efficient drug development model," said Mr. Machado. "I am
excited to work with the Roivant team in the years ahead."
About Patrick Machado
Mr. Machado was a co-founder of Medivation, Inc., where he
served as Chief Financial Officer for over a decade, from 2004 to
2014. He was also Chief Business Officer at Medivation from 2009 to
2014 and served on its Board of Directors from 2014 to 2016. Mr.
Machado also serves on the boards of directors of other
biopharmaceutical companies. He graduated from Santa Clara University summa cum laude with a BA in
German and a BS in Economics, and received his JD from Harvard Law School.
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on
completing the development of promising late-stage drug candidates
with the potential to improve the lives of patients and their
families. Roivant's mission is to reduce the time and cost of
developing new medicines for patients and to share those savings
with the broader healthcare system.
Roivant delivers R&D solutions to its industry partners by
helping them unlock value from their pipelines and realize the full
potential of their research by completing the product development
cycle. Roivant's clinical development pipeline spans multiple
therapeutic areas through strategic alliances, collaborations, and
partnerships with academic institutions and pharmaceutical
companies, including Takeda Pharmaceuticals, Eisai,
GlaxoSmithKline, Vertex Pharmaceuticals, Duke
University, and Cincinnati Children's Hospital.
Roivant Sciences Ltd. is the majority controlling shareholder of
Axovant Sciences Ltd. (NYSE: AXON) and a significant minority
shareholder of Arbutus Biopharma Corporation (NASDAQ:
ABUS).
For additional information, visit www.roivant.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/patrick-machado-joins-board-of-directors-of-roivant-sciences-300347872.html
SOURCE Roivant Sciences Ltd.